– USA, CA – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced the appointment of David Moore to its Board of Directors, bringing a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical and biotech companies and within private equity.
About David Moore
David Moore serves as EVP, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., the US operating subsidiary of Novo Nordisk A/S. He has held positions of increasing responsibility at Novo Nordisk, including VP, Corporate Development, and SVP, Commercial at Novo Nordisk, Inc. Mr. Moore’s other experience also includes serving as an investment partner at Gurnet Point Capital, a life science-focused private equity firm; CEO of Lysovant Sciences, a Roivant company; and president and CCO of Cempra Pharmaceuticals. Mr. Moore began his career at Johnson & Johnson, where he spent 14 years in roles of increasing responsibility across sales, marketing, and business development.
David Moore holds an MBA in Marketing from Lehigh University and a Bachelor of Science in Biology from Towson University.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications.
For more: https://www.corvuspharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.